How do you approach maintenance therapy for relapsed follicular lymphoma?

In general, patients who received 2 years of maintenance rituximab in first-line settings are unlikely to benefit from more maintenance rituximab in second-line. This is especially true if relapse occurs within 24 months of first-line therapy.

A meta-analysis (JNCI 2011) did show a small benefit in o...